Obesity and prostate enlargement in men with localized prostate cancer.
Summary of "Obesity and prostate enlargement in men with localized prostate cancer."
Study Type - Prevalence (retrospective cohort) Level of Evidenceâ€ƒ2b What's known on the subject? and What does the study add? Obesity is associated with prostate enlargement in men without prostate cancer. This study demonstrates an association between obesity and prostate enlargement in men with prostate cancer, and leads to possible implications for prostate cancer screening and diagnosis.
â€¢â€‚To determine if obesity is associated with prostate size in men with prostate cancer. PATIENTS AND
â€¢â€‚We examined preoperative body mass index (BMI) and whole prostate weight in a cohort of 16Â 325 patients undergoing radical prostatectomy for localized prostate cancer from 1975 to 2008 at a single institution. â€¢â€‚We used multivariable regression modelling adjusting for age, year of surgery, preoperative serum prostate-specific antigen (PSA), pathological stage and Gleason grade.
â€¢â€‚Of the entire cohort, 13Â 343 (82%) patients had a prostate weight of at least 40Â g. These men were older (P < 0.001), had a higher preoperative BMI (P < 0.002), higher preoperative PSA (P < 0.001), and were more likely to have pT2 disease (P < 0.001). â€¢â€‚In multivariable regression, preoperative BMI was associated with increased prostate weight: for each 1Â kg/m(2) increase in BMI, prostate weight increased by 0.45Â g (95% CI 0.35-0.55, P-trend < 0.001). â€¢â€‚Compared with men with BMI < 25Â kg/m(2) , men with a BMI â‰¥35Â kg/m(2) had a 40% (odds ratio 1.40, 95% CI 1.01-1.95) increased risk of prostate weight of at least 40Â g and a 70% (odds ratio 1.70, 95% CI 1.32-2.20) increased risk of prostate weight of at least 50Â g.
â€¢â€‚In men with localized prostate cancer, obesity is associated with an increased risk of prostate enlargement. â€¢â€‚These data validate other observations linking obesity with prostate enlargement and may have important ramifications for prostate cancer diagnosis in obese men.
Division of Urology, Department of Surgery, UC San Diego Medical Center, San Diego, CA The Brady Urological Institute, The Johns Hopkins Medical Institution, Baltimore, MD Department of Surgery, Durham VA Medical Center, Durham, VA Division of Urologic Su
This article was published in the following journal.
Name: BJU international
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21736693
- DOI: http://dx.doi.org/10.1111/j.1464-410X.2011.10227.x
Medical and Biotech [MESH] Definitions
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Prostatic Secretory Proteins
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
Ultrasound, High-intensity Focused, Transrectal
Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).
Transurethral Resection Of Prostate
Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Prostate enlargement is common with aging and obesity. We investigated the association between obesity and prostate cancer controlling for differential detection related to prostate enlargement. In an...
BACKGROUND: Metastatic prostate cancer is an incurable disease. During the development of this disease, prostate cancer cells enter the bloodstream as single cells or clusters of cells. Prostate fibro...
Prostate cancer is the most common cancer among American men. It varies widely in aggressiveness, ranging from completely indolent to highly aggressive. Currently, predicting the natural history of a...
Adiponectin is a protein derived from adipose tissue suspected to have an important role in prostate carcinogenesis. Variants in the adiponectin gene (ADIPOQ) and its type 1 receptor (ADIPOR1) have be...
Debate about the use of prostate-specific antigen (PSA) tests to screen prostate cancer in men is ongoing. Prostate cancer is the most common cancer after skin cancer in men and the second most deadly...
The aim of this clinical study is to determine the optimal treatment conditions to achieve prostate cancer tumor ablation and to assess the effects of WST11 mediated VTP treatment in patie...
This study is aimed at providing further clinical evidence to support or refute the current understanding of biological sensitivity of prostate cancer to fractionated radiotherapy. Determi...
Men, 45 years of age or older, with localized prostate cancer will be injected once with a ready made paste including 600 mg 2-hydroxyflutamide (Liproca Depot) into the site of the prostat...
RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment...
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. R-flurbiprofen may be effective in delaying the recurrence of locali...